Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5035 participants.

Also called NCT02867813

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 5,035 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02867813
  • EudraCT 2015-004780-36
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Hungary, Poland, Russia, Slovakia, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02867813. Allocation not applicable; no masking; primary purpose treatment. Start 2016-09-02 (actual); primary completion 2022-03-21 (actual). Results posted on 2023-02-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
Acronym
FOURIER OLE
Condition
Dyslipidemia
Intervention (Biological)
Evolocumab
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct02867813
Content hash
e16a7d116caaafb3843088282e723902973575ad7dd7ab24171c85a791800e95